Phase 3, randomized, double ‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

ConclusionsAt 24 weeks, teneligliptin was generally well tolerated and effective in Chinese T2DM patients with inadequately controlled with diet and exercise.

Source: Journal of Diabetes Investigation - August 17, 2020 Category: Endocrinology Authors: Linong Ji, Jianhua Ma, Weiping Lu, Jingdong Liu, Jiao ’e Zeng, Jialin Yang, Wei Li, Xiuzhen Zhang, Xinhua Xiao, Gen Takayanagi, Yi Wang Tags: CLINICAL TRIAL Source Type: research